French CROs have eye on niche market

By staff reporter

- Last updated on GMT

Related tags: Clinical trial, Pre-clinical development

Two French contract research organisations (CROs) that specialise
in ophthalmology have banded together to offer specialised services
to this niche market.

The merger is being dubbed by the firms as unique, in that it "establishes the first global drug-development services provider to be totally dedicated to ophthalmology".​ However, the amalgamation is seemingly just a formalisation of an existing relationship between the two CROs - they were both established within five years of each other by the same person, Pierre-Paul Elena, who has also served as president for the two companies. Iris Pharma's focus is on preclinical research in the field, while Clirophtha runs Phase I-IV clinical trials throughout Western and Eastern Europe, North Africa, India, South Arabia and North America. Under their new united front, they will offer global customers "a complete range of [ophthalmology] services"​ under the name of Iris Pharma, including bioanalysis; non-GLP pre-formulation; pre-clinical studies and services; clinical trials and supporting functions; and consulting.

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more